Chronic treatment of hydroxytryptamine type 2a receptor antagonist sarpogrelate hydrochloride modulates the vasoreactivity of serotonin in experimental rabbit vein grafts

Journal of Vascular Surgery

Volumn 50, Issue 3, 2009, Pages 617-625

  Kodama, Akio ^a   Komori, Kimihiro ^a   Kajikuri, Junko ^b   Itoh, Takeo ^b  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 (3 DIMETHYLAMINOPROPYL) 4 HYDROXY N [4 (4 PYRIDINYL)PHENYL]BENZAMIDE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; SARPOGRELATE; SEROTONIN; SEROTONIN 1B ANTAGONIST; SEROTONIN 1B RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CAROTID ARTERY; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; JUGULAR VEIN; MALE; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; PRIORITY JOURNAL; RABBIT; REGULATORY MECHANISM; SEROTONIN RELEASE; SMOOTH MUSCLE CONTRACTILITY; VASOSPASM; VEIN GRAFT;

ANIMALS; BENZAMIDES; CAROTID ARTERY, COMMON; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; GRAFT OCCLUSION, VASCULAR; JUGULAR VEINS; MALE; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROARGININE; PYRIDINES; RABBITS; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN; SEROTONIN ANTAGONISTS; SUCCINATES; VASOCONSTRICTION;

EID: 68849090225     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2009.05.065     Document Type: Article

References (27)

1. Jiang Z., Wu L., Miller B.L., Goldman D.R., Fernandez C.M., Abouhamze Z.S., et al. A novel vein graft model: adaptation to differential flow environments. Am J Physiol Heart Circ Physiol 286 (2004) H240-H245
2. Morinaga K., Eguchi H., Miyazaki T., Okadome K., and Sugimachi K. Development and regression of intimal thickening of arterially transplanted autologous vein grafts in dogs. J Vasc Surg 5 (1987) 719-730
3. Komori K. Mechanisms and prevention of intimal thickening of the autogenous vein grafts-possible involvement of nitric oxide. Nagoya J Med Sci 66 (2003) 9-19
4. Chester A., Bodelsson M., Arnekio-Nobin B., Tadjkarimi S., Tornebrandt K., and Yacoub M. Characterization of 5-HT receptors in the human saphenous vein implications for patency of bypass grafts. J Appl Cardiol 5 (1990) 51-59
5. 1B receptor in hypoperfused canine hearts. J Mol Cell Cardiol 37 (2004) 1219-1223
6. Banes A., Florian J.A., and Watts S.W. Mechanisms of 5-hydroxytriptamine (2A) receptor activation of the mitogen-activated protein kinase pathway in vascular smooth muscle. J Pharmacol Exp Ther 291 (1999) 1179-1187
7. 1D receptor subtype. J Pharmacol Exp Ther 252 (1990) 387-395
8. Bhattacharya A., Schenck K.W., Xu Y.C., Nisenbaum L., Galbreath E., and Cohen M.L. 5-Hydroxytryptamine 1β receptor-mediated contraction of rabbit saphenous vein and basilar artery: role of vascular endothelium. J Pharmacol Exp Ther 309 (2004) 825-832
9. Saini H.K., Takeda N., Goyal R.K., Kumamoto H., Arneja A.S., and Dhalla N.S. Therapeutic potentials of sarpogrelate in cardiovascular disease. Cardiovasc Drug Rev 22 (2004) 27-54
10. Nakamura K., Kariyazono H., Masuda H., Sakata R., and Yamada K. Effects of sarpogrelate hydrochloride on adenosine diphosphate- or collagen-induced platelet responses in arteriosclerosis obliterans. Blood Coagul Fibrinolysis 12 (2001) 391-397
11. 2A antagonist, improves vascular function in patients with peripheral arterial disease. J Cardiovasc Pharmacol 49 (2007) 221-227
12. 2 receptor antagonist, reduces stenosis induced by balloon injury in the hypercholesterolaemic rabbit. Int Angiol 16 (1997) 204-209
13. Kodama A., Komori K., Hattori K., Yamanouchi D., Kajikuri J., and Itoh T. Sarpogrelate hydrochloride reduced intimal hyperplasia in experimental rabbit vein graft. J Vasc Surg 49 (2009) 1272-1281
14. 2A antagonist, retards the progression of atherosclerosis through a novel mechanism. Atherosclerosis 168 (2003) 23-31
15. Banno H., Takei Y., Muramatsu T., Komori K., and Kadomatsu K. Controlled release of small interfering RNA targeting midkine attenuates intimal hyperplasia in vein grafts. J Vasc Surg 44 (2006) 633-641
16. Yamanouchi D., Banno H., Nakayama M., Sugimoto M., Fujita H., Kobayashi M., et al. Hydrophilic statin suppresses vein graft intimal hyperplasia via endothelial cell-tropic Rho-kinase inhibition. J Vasc Surg 42 (2005) 757-764
17. Kusama N., Kajikuri J., Watanabe Y., Suzuki Y., Katsuya H., and Itoh T. Characteristics of attenuated endothelium-dependent relaxation seen in rabbit intrapulmonary vein following chronic nitroglycerine administration. Br J Pharmacol 145 (2005) 193-202
18. Makhoul R.G., Davis W.S., Mikat E.M., McCann R.L., and Hagen P.O. Responsiveness of vein bypass grafts to stimulation with norepinephrine and 5-hydroxytriptamine. J Vasc Surg 6 (1987) 32-38
19. MacAlpin R.N. Contribution of dynamic vascular wall thickening to luminal narrowing during coronary artery constriction. Circulation 61 (1980) 296-301
20. Radic Z.S., O'Donohoe M.K., Schwartz L.B., Stein A.D., Mikat E.M., McCann R.L., and Hagen P.O. Alterations in serotonergic receptor expression in experimental vein grafts. J Vasc Surg 14 (1991) 40-47
21. Cocks T.M., and Angus J.A. Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin. Nature 305 (1983) 627-630
22. Komori K., Gloviczki M.N., Bourchier R.G., Miller V.M., and Vanhoutte P.M. Endothelium-dependent vasorelaxations in response to aggregating platelets are impaired in reversed vein graft. J Vasc Surg 12 (1990) 139-147
23. Okazaki J., Komori K., Kawasaki K., Eguchi D., Ishida M., and Sugimachi K. L-arginine inhibits smooth muscle cell proliferation of vein graft intimal thickness in hypercholesterolemic rabbits. Cardiovasc Res 36 (1997) 429-436
24. 2A receptor antagonist in intermittent claudication. A phase II European study. Vasc Med (London, England) 11 (2006) 75-83
25. Yamaguchi H., Furukawa K., Sakano T., Yoshizaki S., and Nakamura M. Efficacy and safety of sarpogrelate hydrochloride (MCI-9042) in the long-term treatment of patients with chronic arterial occlusive disease. [in Japanese]. Jpn J Clin Pharmacol Ther 7 (1991) 1771-1782
26. 2 receptor antagonist sarpogrelate (MCI-9042) treatment on platelet function in Buerger's disease. Thromb Res 84 (1996) 445-452
27. Shinohara Y., Nishimaru K., Sawada T., Terashi A., Handa S., Hirai S., et al. Sarpogrelate-aspirin comparative clinical study for efficacy and safety in secondary prevention of cerebral infarction (S-ACCESS): a randomized, double-blind, aspirin-controlled trial. Stroke 39 (2008) 1827-1833